184 related articles for article (PubMed ID: 24476504)
1. Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin.
Requena A; Cruz M; Ruiz FJ; García-Velasco JA
Reprod Biol Endocrinol; 2014 Jan; 12():10. PubMed ID: 24476504
[TBL] [Abstract][Full Text] [Related]
2. Recombinant follicular stimulating hormone plus recombinant luteinizing hormone versus human menopausal gonadotropins- does the source of LH bioactivity affect ovarian stimulation outcome?
Kirshenbaum M; Gil O; Haas J; Nahum R; Zilberberg E; Lebovitz O; Orvieto R
Reprod Biol Endocrinol; 2021 Dec; 19(1):182. PubMed ID: 34886872
[TBL] [Abstract][Full Text] [Related]
3. Highly purified hMG versus recombinant FSH plus recombinant LH in intrauterine insemination cycles in women ≥35 years: a RCT.
Moro F; Scarinci E; Palla C; Romani F; Familiari A; Tropea A; Leoncini E; Lanzone A; Apa R
Hum Reprod; 2015 Jan; 30(1):179-85. PubMed ID: 25398971
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the combination of recombinant follicle-stimulating hormone and recombinant luteinizing hormone protocol versus human menopausal gonadotropin protocol in controlled ovarian stimulation: A systematic review and meta-analysis.
Wang Y; Li L; Deng K; Liu J; Liu Y; Zou K; Hao G; Sun X
J Evid Based Med; 2020 Aug; 13(3):215-226. PubMed ID: 32627395
[TBL] [Abstract][Full Text] [Related]
5. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
[TBL] [Abstract][Full Text] [Related]
6. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.
Carone D; Caropreso C; Vitti A; Chiappetta R
J Endocrinol Invest; 2012 Dec; 35(11):996-1002. PubMed ID: 23095369
[TBL] [Abstract][Full Text] [Related]
8. Effects of urinary and recombinant gonadotropins on in vitro maturation outcomes of mouse preantral follicles.
Park KE; Ku SY; Jung KC; Liu HC; Kim YY; Kim YJ; Kim SH; Choi YM; Kim JG; Moon SY
Reprod Sci; 2013 Aug; 20(8):909-16. PubMed ID: 23239820
[TBL] [Abstract][Full Text] [Related]
9. In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review.
Trew GH; Brown AP; Gillard S; Blackmore S; Clewlow C; O'Donohoe P; Wasiak R
Reprod Biol Endocrinol; 2010 Nov; 8():137. PubMed ID: 21059191
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain.
Burgués S;
Hum Reprod; 2001 Dec; 16(12):2525-32. PubMed ID: 11726569
[TBL] [Abstract][Full Text] [Related]
11. Implications of using follicle-stimulating hormone preparations depleted of luteinizing hormone to achieve follicular growth in in vitro fertilization.
Agrawal R; Conway GS; Engmann L; Bekir JS; Jacobs HS
Gynecol Endocrinol; 1998 Feb; 12(1):9-15. PubMed ID: 9526704
[TBL] [Abstract][Full Text] [Related]
12. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. II. Comparison of hMG and recombinant FSH.
Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM
Int J Fertil Womens Med; 1997; 42(6):431-5. PubMed ID: 9459089
[TBL] [Abstract][Full Text] [Related]
13. Follicular fluid hormone concentrations after ovarian stimulation using gonadotropin preparations with different FSH/LH ratios. I. Comparison of an FSH-dominant and a purified FSH preparation.
Duijkers IJ; Willemsen WN; Hollanders HM; Hamilton CJ; Thomas CM; Vemer HM
Int J Fertil Womens Med; 1997; 42(5):306-10. PubMed ID: 9406836
[TBL] [Abstract][Full Text] [Related]
14. Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.
Revelli A; Pettinau G; Basso G; Carosso A; Ferrero A; Dallan C; Canosa S; Gennarelli G; Guidetti D; Filippini C; Benedetto C
Reprod Biol Endocrinol; 2015 Jul; 13():77. PubMed ID: 26209525
[TBL] [Abstract][Full Text] [Related]
15. [The influence of exogenous LH/hCG activity on serum progesterone levels on the day of hCG administration in in vitro fertilization].
Sebag-Peyrelevade S; El Hachem H; Gallot V; Genro VK; Fanchin R
J Gynecol Obstet Biol Reprod (Paris); 2015 Jun; 44(6):524-31. PubMed ID: 25236690
[TBL] [Abstract][Full Text] [Related]
16. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
Smitz J; Andersen AN; Devroey P; Arce JC;
Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
[TBL] [Abstract][Full Text] [Related]
17. Urinary hMG (Meropur) versus recombinant FSH plus recombinant LH (Pergoveris) in IVF: a multicenter, prospective, randomized controlled trial.
Pacchiarotti A; Sbracia M; Frega A; Selman H; Rinaldi L; Pacchiarotti A
Fertil Steril; 2010 Nov; 94(6):2467-9. PubMed ID: 20537626
[TBL] [Abstract][Full Text] [Related]
18. A comparison of outcomes from in vitro fertilization cycles stimulated with either recombinant luteinizing hormone (LH) or human chorionic gonadotropin acting as an LH analogue delivered as human menopausal gonadotropins, in subjects with good or poor ovarian reserve: a retrospective analysis.
Dahan MH; Agdi M; Shehata F; Son W; Tan SL
Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():70-3. PubMed ID: 24314801
[TBL] [Abstract][Full Text] [Related]
19. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
[TBL] [Abstract][Full Text] [Related]
20. Reduction of dehydroepiandrosterone sulfate synthesis in women with polycystic ovary syndrome by human menopausal gonadotropin but not purified urinary follicle stimulating hormone: a comparative pilot study.
Turkmen S; Backstrom T; Idil M
Gynecol Endocrinol; 2004 Aug; 19(2):69-78. PubMed ID: 15624268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
